Edition:
India

Aviragen Therapeutics Inc (AVIR.OQ)

AVIR.OQ on NASDAQ Stock Exchange Capital Market

0.59USD
1:47am IST
Change (% chg)

$-0.00 (-0.71%)
Prev Close
$0.59
Open
$0.60
Day's High
$0.60
Day's Low
$0.57
Volume
13,823
Avg. Vol
98,633
52-wk High
$1.48
52-wk Low
$0.44

Chart for

About

Aviragen Therapeutics, Inc., formerly Biota Pharmaceuticals, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options. Its... (more)

Overall

Beta: 0.02
Market Cap(Mil.): $27.05
Shares Outstanding(Mil.): 38.65
Dividend: --
Yield (%): --

Financials

BRIEF-Aviragen Therapeutics Completes Patient Enrollment In Phase 2 Clinical Trial For Condyloma Treatment

* AVIRAGEN THERAPEUTICS ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE 2 CLINICAL TRIAL OF TESLEXIVIR (BTA074) FOR THE TREATMENT OF CONDYLOMA

29 Nov 2017

BRIEF-SC Fundamental Value Fund LP says ‍​believes that liquidation of Aviragen Therapeutics is superior to Vaxart's proposed transaction

* SC Fundamental Value Fund LP says ‍​believes that liquidation of Aviragen Therapeutics Inc is superior to Vaxart Inc's proposed transaction - SEC Filing

09 Nov 2017

BRIEF-Aviragen Therapeutics Q1 loss per share $0.14

* Aviragen Therapeutics reports first quarter of fiscal year 2018 financial results

02 Nov 2017

BRIEF-Aviragen Therapeutics to pay Vaxart $1.95 mln, if deal terminated

* On termination of merger under specified circumstances, co required to pay Vaxart termination fee of $1.95 million ​- SEC filing

30 Oct 2017

BRIEF-Aviragen Therapeutics and Vaxart enter into merger agreement

* Aviragen Therapeutics and Vaxart enter into merger agreement

30 Oct 2017

BRIEF-Aviragen Therapeutics reports Q4 loss per share $0.15

* Aviragen therapeutics reports fourth quarter and fiscal year 2017 financial results

01 Sep 2017

BRIEF-SC Fundamental Value Fund LP reports 5.01 pct stake in Aviragen Therapeutics Inc as of June 21

* SC Fundamental Value Fund Lp reports 5.01 percent stake in Aviragen Therapeutics Inc as of June 21 - SEC filing Source text - (http://bit.ly/2tsaxus) Further company coverage:

30 Jun 2017

Earnings vs. Estimates